Mortality Up With Spontaneous Bleeding After PCI

Share this content:
Mortality Up With Spontaneous Bleeding After PCI
Mortality Up With Spontaneous Bleeding After PCI

MONDAY, April 13, 2015 (HealthDay News) -- For patients undergoing percutaneous coronary intervention (PCI), spontaneous bleeding is associated with increased risk of death, comparable to that associated with myocardial infarction (MI), according to a study published in the April 14 issue of the Journal of the American College of Cardiology.

Dhruv S. Kazi, M.D., from the San Francisco General Hospital, and colleagues examined data for 32,906 patients who had a PCI and survived the index hospitalization. The authors assessed the correlations between spontaneous bleeding and MI after PCI and all-cause mortality.

The researchers found that between seven and 365 days after discharge, 530 of the patients had bleeds and 991 had MIs. Over a mean follow-up of 4.42 years, there were 4,048 deaths. The crude annual death rate was elevated after patients experienced a spontaneous bleed or MI compared with patients who experienced neither event (9.5 and 7.6 percent, respectively, versus 2.6 percent). There was an increased rate of death in association with bleeding (adjusted hazard ratio, 1.61) which was comparable to that seen with MI (adjusted hazard ratio, 1.91). After additional adjustment for longitudinal use of antiplatelet agents, the association of bleeding with death remained significant.

"This trade-off between efficacy and safety bolsters the argument for personalizing antiplatelet therapy after PCI on the basis of the patient's long-term risk of both thrombotic and bleeding events," the authors write.

One author disclosed financial ties to Genentech.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »